New Retina Radio
New Retina Radio

02.11.22

Exploring the clinical development program for an innovative, continuous delivery treatment for nAMD

Recently, the first refillable, intraocular device that enables continuous delivery of therapy was FDA approved for nAMD. John Kitchens, MD sits down with one of the investigators, Dante Pieramici, MD, to learn more about his experiences with the clinical development program and this innovative drug delivery system. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.

View full description +

MORE EPISODES

09.04.25

ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR

David Lally, MD; and Ehsan Rahimy, MD

08.21.25

ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders

John Kitchens, MD; Krishna Mukkamala, MD

07.21.25

The State of Geographic Atrophy Around the Globe: Part 2 of 2

Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD; Daniel Ting, MD, PhD

07.21.25

The State of Geographic Atrophy Around the Globe: Part 1 of 2

Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD; Daniel Ting, MD, PhD

07.18.25

Diabetic Retinopathy Severity and Income Status

Ben Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD

07.07.25

GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing Therapy

Judy Kim, MD; Sunir Garg, MD; Deepak Sambhara, MD; and Rishi Singh, MD

07.07.25

GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates

Judy Kim, MD; Sunir Garg, MD; Deepak Sambhara, MD; and Rishi Singh, MD

Show More